Clinical trial
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple…
NCT00097188 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00097188 |
|---|---|
| Title | A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis |
| Official title | A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 104 |
| Start date | Dec 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Nov 19, 2004 |
| Last update posted | Mar 4, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: